Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
Advances in CAR T-Cell Therapy for Multiple Myeloma
MedPage Today· 1 day agoB-cell maturation antigen (BCMA)-directed CAR T-cell therapies are now established options for treating multiple myeloma after relapse, but efforts are...
Quadruplet Regimens Have Become Standard for Multiple Myeloma
MedPage Today· 1 day agoWhile triplet regimens were once standard for newly diagnosed multiple myeloma, more recent studies...
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease...
Benzinga via Yahoo Finance· 2 days agoOn Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional...
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible...
Benzinga· 5 days agoLicense Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible ...
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
Zacks via Yahoo Finance· 5 days agoThe FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 18 hours agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
FDA accepts Sanofi’s Sarclisa sBLA for priority review
Pharmaceutical Technology via Yahoo Finance· 4 days agoSanofi is seeking approval for Sarclisa, a monoclonal antibody, in combination with bortezomib,...
Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com
Investing.com· 3 days agoBioLineRx (BLRX) has reported its financial results for the first quarter of 2024, highlighting...
Helmer's glue: Retired IU track coach Ron, son Justin team up at Bloomington North
The Herald-Times via Yahoo Sports· 22 hours ago"Then this winter, I made the comment again and it led to a little bit of discussion. Oh, maybe he...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 1 day agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.